AstraZeneca PLC $AZN Shares Acquired by Acadian Asset Management LLC

Acadian Asset Management LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 2,389.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,043,850 shares of the company’s stock after purchasing an additional 1,961,764 shares during the period. Acadian Asset Management LLC owned 0.07% of AstraZeneca worth $142,798,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. NewSquare Capital LLC lifted its holdings in AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after buying an additional 289 shares during the last quarter. Richardson Financial Services Inc. increased its holdings in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of AstraZeneca in the 1st quarter worth $29,000. Finally, Maseco LLP acquired a new position in AstraZeneca in the second quarter valued at $34,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN opened at $84.58 on Friday. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57. The firm has a market cap of $262.32 billion, a price-to-earnings ratio of 31.80, a PEG ratio of 1.52 and a beta of 0.34. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $81.41 and a 200 day simple moving average of $75.55.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.08 EPS. Equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.